Roche Settles Patent Row With Intas Over Cancer Drug Xeloda

Law360, New York (June 25, 2013, 4:58 PM EDT) -- A New Jersey federal judge on Monday dismissed a Hoffmann-La Roche Inc. lawsuit contending Intas Pharmaceuticals Ltd. and a subsidiary infringed a patent for Roche's Xeloda cancer drug by seeking approval for a generic version of the treatment, after the parties reached a settlement.

U.S. District Judge Esther Salas dismissed the case in a one-page order that said both parties will bear their own costs. A spokesperson for Roche Group unit Genentech told Law360 that Intas and the subsidiary, Accord Healthcare Inc. have entered a nonexclusive...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.